Results for fiscal year 2025 March 17, 2026Net income, Group share: €348 million Proposed ordinary dividend of €0.08 and exceptional dividend of €1.5 per share Revenue: €2,926 million, -9% at constant scope and exchange rates. Adjusted operating income (EBITA(1) (2)): €286 million including the results of the equity-accounted associates UMG, Canal+, Louis Hachette Group, Havas and Vivendi for the full year 2025. Net income: €351 million, compared with €1,840 million in 2024, which included the net capital gain on the disposal of Bolloré Logistics (+€3.6 billion) and the capital loss on the deconsolidation of companies resulting from the spin-off of Vivendi (-€1.9 billion). Net income, Group share: €348 million. Net cash position: €5,619 million at December 31, 2025 (compared with €5,306 million...

FY 2025 Sales Growth of 72% to $9.7 Million Driven by Strong Demand for Battery Products, Accessories and Technologies Next Generation Products for Industrial and Construction Applications to Expand Market Opportunities REDMOND, Ore., March 17, 2026 (GLOBE NEWSWIRE) — Expion360 Inc. (Nasdaq: XPON) (“Expion360” or the “Company”), an industry leader in lithium iron phosphate (“LiFePO4”) battery power storage solutions, today reported its financial and operational results for the fourth quarter and year ended December 31, 2025. Year Ended 2025 and Subsequent Financial and Operational HighlightsNet sales for the year ended December 31, 2025 totaled $9.7 million, a 72% increase compared to $5.6 million for the same period in 2024. Gross profit for the year ended December 31, 2025 totaled $1.3 million, a 16% increase compared to $1.2...

Record quarterly revenue in fourth quarter of $28.9M, +58% year-over-year growth; IFRS gross margin of 75.6% Fourth quarter pulse recurring revenue of $13.2M, +83% year-over-year growth Full fiscal year 2025 revenue of $87.6M, +47% year-over-year growth; IFRS gross margin of 75.3% Company achieves net profitability with full fiscal year 2025 IFRS and non-IFRS net income of $5.5M and $7.8M, respectively, versus a net loss of $4.5M and $2.1M, respectively, in the same period last year Approximately 2,700 Sofwave systems sold to date and more than 770,000 Sofwave treatments administered since commercialization Installed base continues to expand globally with systems placed across more than 50 countriesSAN CLEMENTE, Calif., March 17, 2026 (GLOBE NEWSWIRE) — Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based...

Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027 Intend to initiate Phase 3 clinical trials by year-end 2027 Completed oversubscribed $50.0 million private placement in December 2025 $118.0 million in cash, cash equivalents and marketable securities as of December 31, 2025 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) — Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the full year ended December 31, 2025 and provided business...

Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2026; proven medical device leader with more than 30 years of experience scaling commercial healthcare businesses MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of...

Q4 GAAP revenue of $104.5 million increased 317.7% year-over-year, driven by recently closed M&A transactions On a pro forma basis, Q4 same store sales increased 22% year-over-year and wholesale revenue increased 55% year-over-year; excluding Minnesota, same store sales increased 11.3% year-over-year Announced the pending acquisitions of Eaze, Schwazze, and PharmaCann retail assets in Colorado, and MOU for the acquisition of Hawthorne, all of which are expected to close in the first half of 2026 Company closed Q4 with $122.5 million in cash; expects to remain acquisitive MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today reported financial results for its fourth fiscal quarter ended December 31, 2025. Key financial results are presented below in summary...

OTTAWA, Ontario, March 17, 2026 (GLOBE NEWSWIRE) — Telesat (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three and twelve-month periods ended December 31, 2025. All amounts are in Canadian dollars and reported under IFRS® Accounting Standards unless otherwise noted. “Telesat made strong progress on multiple fronts in 2025,” commented Dan Goldberg, Telesat’s President and CEO. “The development of the Telesat Lightspeed constellation – the satellites, associated software, user terminals, and landing stations – continues to move forward at a rapid pace. We’re seeing strong interest in Telesat Lightspeed from customers across our target market segments, with demand from government users for defence and sovereignty requirements being particularly...

Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026 Newly announced unblinded safety data from MRT-8102 SAD/MAD cohorts continue to support favorable safety/tolerability profile and wide therapeutic window Company plans to initiate multiple Phase 2 studies of MRT-8102, including in patients with elevated CVD-risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 Presented positive interim data from the Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide showing 100% PSA response rate in metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations Phase...

SHANGHAI, China, March 17, 2026 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsNet revenue increased by 8.6% year-over-year (“Y-o-Y”) to RMB2,921.7 million (US$417.8 million) in the fourth quarter of 2025 (4Q2024: RMB2,690.7 million). Net loss1 was RMB462.8 million (US$66.2 million) in the fourth quarter of 2025 (4Q2024: RMB173.4 million). Net loss margin was 15.8% in the fourth quarter of 2025 (4Q2024: 6.5%). Adjusted EBITDA (non-GAAP) increased by 5.2% Y-o-Y to RMB1,365.6 million (US$195.3 million) in the fourth quarter of 2025 (4Q2024: RMB1,297.7...

– Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 – – Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for the Treatment of WHIM Syndrome in the European Union – – Balance Sheet Provides Cash Runway through 2028 – BOSTON, March 17, 2026 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update. “Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver life-changing therapies to people living with rare blood diseases,” said Adam Craig, M.D., Ph.D., Executive Chairman...